We analyzed Eli Lilly’s tech-focused acquisitions, investments, and partnerships to discern the company’s strategic priorities.
What you need to know:
- Eli Lilly is using technology to reengineer how it develops treatments, leveraging AI to speed up drug discovery.
- The company is investing in novel drug delivery methods, such as targeted delivery systems, to improve treatment efficacy and the patient experience.
- Lilly is rapidly expanding its direct-to-consumer approach through LillyDirect, partnering with telehealth providers and integrating with digital pharmacies to streamline drug distribution and improve patient access.
Eli Lilly is using technology to reengineer how it develops and delivers treatments.
The pharma giant is employing AI to speed up drug discovery in its main research areas, with the goal of identifying promising drug candidates faster and more efficiently than is possible with traditional methods.
Lilly is also investing in next-generation drug delivery technologies, such as targeted delivery systems, to improve treatment efficacy and the patient experience.
In early 2024, Lilly launched LillyDirect — a significant move toward a direct-to-consumer healthcare model that could bypass traditional drug distribution.
Using CB Insights data, we uncovered 4 strategic priorities highlighted by Eli Lilly’s acquisitions, investments, and partnerships since Q1’23. We then categorized companies by their relationships with Lilly across these priorities:
- AI-powered drug discovery
- Digital patient monitoring and diagnostics
- Drug delivery
- D2C healthcare
- Digital pharmacy tech
- Telehealth prescribing platforms
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
